S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
UK
LSE
Okyo Pharma Limited (OKYO)
Okyo Pharma Limited (OKYO) News

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:OKYO

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
11/26/2024	6:00AM	UK Regulatory	OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference	LSE:OKYO	Okyo Pharma Limited
10/30/2024	6:00AM	UK Regulatory	OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference	LSE:OKYO	Okyo Pharma Limited
10/23/2024	6:00AM	UK Regulatory	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
10/16/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
09/10/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
09/05/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
08/27/2024	6:00AM	UK Regulatory	OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease	LSE:OKYO	Okyo Pharma Limited
08/23/2024	8:00AM	UK Regulatory	OKYO Pharma CEO Interview to Air on Bloomberg TV	LSE:OKYO	Okyo Pharma Limited
08/23/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
08/21/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
08/15/2024	11:13AM	UK Regulatory	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference	LSE:OKYO	Okyo Pharma Limited
08/06/2024	6:00AM	UK Regulatory	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use	LSE:OKYO	Okyo Pharma Limited
07/11/2024	6:00AM	UK Regulatory	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101	LSE:OKYO	Okyo Pharma Limited
07/10/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease	LSE:OKYO	Okyo Pharma Limited
05/08/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Participation in May 2024 Investor Conferences	LSE:OKYO	Okyo Pharma Limited
04/30/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	LSE:OKYO	Okyo Pharma Limited
04/08/2024	6:00PM	UK Regulatory	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	LSE:OKYO	Okyo Pharma Limited
04/02/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	LSE:OKYO	Okyo Pharma Limited
03/22/2024	6:00AM	UK Regulatory	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	LSE:OKYO	Okyo Pharma Limited
03/21/2024	6:00AM	UK Regulatory	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	LSE:OKYO	Okyo Pharma Limited
03/20/2024	6:00AM	UK Regulatory	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	LSE:OKYO	Okyo Pharma Limited
02/09/2024	6:36AM	InvestorsHub NewsWire	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
02/09/2024	6:00AM	UK Regulatory	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
01/31/2024	6:00AM	UK Regulatory	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	LSE:OKYO	Okyo Pharma Limited
05/22/2023	2:15AM	UK Regulatory	OKYO Pharma Limited London Stock Exchange Delisting	LSE:OKYO	Okyo Pharma Limited
05/22/2023	2:00AM	UK Regulatory	London Stock Exchange Notice Cancellation - OKYO PHARMA LIMITED	LSE:OKYO	Okyo Pharma Limited
05/19/2023	5:22AM	Alliance News	IN BRIEF: Okyo Pharma to move shares to New York with London delisting	LSE:OKYO	Okyo Pharma Limited
05/19/2023	2:00AM	RNS Non-Regulatory	OKYO Pharma Limited ADS Program collapse	LSE:OKYO	Okyo Pharma Limited
05/15/2023	1:00AM	UK Regulatory	OKYO Pharma Limited Change of Record Time and Last Day of Dealings	LSE:OKYO	Okyo Pharma Limited
05/11/2023	8:27AM	Alliance News	IN BRIEF: Okyo Pharma delays delisting from London trading to May 22	LSE:OKYO	Okyo Pharma Limited

Showing the most relevant articles for your search:LSE:OKYO

1 2 3 4 5 6 7 8 9 10 Next >>

Global Developments (PK)

Anavex Life Sciences

Digital Brand Media and ... (PK)

Asia Broadband (PK)

GNCC Capital (CE)

FuelCell Energy

Accredited Solutions (PK)

Quantum Computing

Super Micro Computer

TransCode Therapeutics

Code Green Apparel (PK)

Clean Vision (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions